Compare Royal Caribbean Cruises Ltd (RCL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs Zimmer Biomet Holdings Inc — how do they compare? Royal Caribbean Cruises Ltd trades at $280.43 (market cap $75.26B), while Zimmer Biomet Holdings Inc trades at $89.01 (market cap $16.95B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 4.4× Zimmer Biomet Holdings Inc's market cap, and Royal Caribbean Cruises Ltd pays the higher dividend (2.13%). Which is the better fit depends on your goals — on Pluang, investors hold Royal Caribbean Cruises Ltd for 85 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| RCL | ZBH | |
|---|---|---|
Market Cap | $75.26B | $16.95B |
Volume | 1,958,628 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $348.03 | $103.98 |
52-Week Low | $230.30 | $79.58 |
Typical Hold Time | 85 Days | 89 Days |
Enterprise Value | $97.91B | $24.02B |
Dividend Yield | 2.13% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $280.65, down 0.61% on the day, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 2025 revenue of $17.93B, net income of $4.27B (23.54% margin), and consistent earnings beats in recent quarters. Recent news highlights include a $3B investment in Sandals Resorts and positive analyst sentiment with 52.83% buy ratings.
RCL presents a compelling growth story with strong profitability and expansion initiatives, though risks include high debt levels and fuel cost exposure. The consensus price target of $346.67 suggests 23.5% upside potential, supported by improving cash flow trends and strategic diversification into resort operations.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
